News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

May 16, 2022

Block Listing Six Monthly Return

16 May 2022 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:   Name of […]
• Read More
May 11, 2022

Result of Annual General Meeting

LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a […]
• Read More
May 9, 2022

AGM dial in details (09.05.22)

The Annual General Meeting of LungLife AI,Inc. the “Company”) to be held at 2:00 p.m. BST on 11 May 2022 at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, United Kingdom (including any adjournment or postponement thereof, the “AGM”). Stockholders will be able to listen live to the AGM by accessing the below Microsoft […]
• Read More
April 8, 2022

Publication of Annual Report and Accounts & Notice of AGM

8 April 2022 LungLife AI, Inc. (the “Company” or “LungLife”)  Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read More
March 28, 2022

LungLife AI (AIM: LLAI) - Preliminary Results

28 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary results LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021. Summary and Highlights for the year: Revenues […]
• Read More
March 17, 2022

LungLife AI (AIM: LLAI) - Veterans Affairs (VA) sites added to validation study with first Veteran enroled

17 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Veterans Affairs (VA) sites added to validation study with first Veteran enroled Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific Advisory Board LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its pivotal clinical study to evaluate the […]
• Read More
March 8, 2022

LungLife AI, Inc. - Notice of Results

8 March 2022 LungLife AI, Inc. (the "Company" or "LungLife") Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2021 on Monday 28 March 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read More
February 2, 2022

LungLife AI - First patient enrolment for LungLB® validation study

2 February 2022 LungLife AI, Inc. (the “Company” or “LungLife”)  First patient enrolment for LungLB® validation study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has enrolled its first patient in its pivotal clinical study to evaluate the LungLB® test in subjects presenting with indeterminate lung nodules. The […]
• Read More
January 4, 2022

LungLife AI, Inc. - CPT® Code granted by American Medical Association

4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”)   CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]
• Read More
November 22, 2021

LungLife AI Clinical Laboratory achieves CAP accreditation

19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”)   LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]
• Read More
1 2 3

Investor inquiries

© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down